Form 4: Enliven Therapeutics Director Sells Shares
Insider Transaction (Form 4)
J. Scott Garland, a Director of Enliven Therapeutics, Inc., sold 13,000 shares of common stock on October 1, 2026 for $46.67 per share.
Summary
- Option exercise/conversion: acquired 13,000 Common Stock at $15.47 ($201,110) on October 1, 2026; holds 13,000 after (Direct).
- Open-market sale: disposed of 13,000 Common Stock at $46.67 ($606,719) on October 1, 2026 (Direct).
- Option exercise/conversion: disposed of 13,000 Stock Option (right to buy) on October 1, 2026; holds 46,372 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $606,719 of stock on the open market.
Insider Transactions
J. Scott Garland — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-01 | Option exercise/conversion | Common Stock | 13,000 | $15 | $201.1K | 13,000 |
| 2026-10-01 | Open-market sale | Common Stock | 13,000 | $47 | $606.7K | 0 |
| 2026-10-01 | Option exercise/conversion | Stock Option (right to buy) | 13,000 | — | — | 46,372 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-01 | Option exercise/conversion (13,000 shares) |
| 2026-10-01 | Open-market sale (13,000 shares) |
| 2026-10-01 | Option exercise/conversion (13,000 shares) |
Keywords
insider transaction, Form 4, ELVN, Enliven Therapeutics, Inc., bearish, J. Scott Garland
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.